Phathom Pharmaceuticals, Inc.
PHAT
$14.75
$0.010.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.97M | -75.81M | -94.32M | -74.45M | -85.58M |
| Total Depreciation and Amortization | 156.00K | 172.00K | 177.00K | 193.00K | 191.00K |
| Total Amortization of Deferred Charges | 775.00K | 734.00K | 696.00K | 629.00K | 589.00K |
| Total Other Non-Cash Items | 16.48M | 18.13M | 17.43M | 19.21M | 19.84M |
| Change in Net Operating Assets | -1.56M | -5.95M | -8.91M | -9.04M | 1.39M |
| Cash from Operations | -14.12M | -62.73M | -84.93M | -63.46M | -63.57M |
| Capital Expenditure | -27.00K | -97.00K | -18.00K | -5.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -27.00K | -97.00K | -18.00K | -5.00K | -44.00K |
| Total Debt Issued | -- | -- | -- | 24.75M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 293.00K | 80.00K | -- | 1.30M | 122.06M |
| Repurchase of Common Stock | -564.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -271.00K | 80.00K | -- | 26.05M | 122.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.41M | -62.75M | -84.95M | -37.42M | 58.44M |